AusCann (ACNNF)

[OSOROJO]

F.Y.I. AUSCANN GROUP HOLDINGS LTD (ASX: AC8) – Its proprietary solid hard-shell capsules for treatment of chronic pain and manufacture release of its first medicinal cannabis product line has been announced by the company and that it has appointed TGA licensed PCI Pharma. They are scheduled to release in H1 2019. The company has cash and cash equivalents as at 30 September 2018 of $43.732 million and with no debt facility which signifies a healthy balance sheet. The company address the medical needs of doctors and their patients develop and produce cannabinoid pharmaceuticals. Following A$35m placement the company is well funded into CY2019. The stock traded at $0.705 as at December 3, 2018 which is near its 52-week low and has seen a performance change of -11.39% in one year.